Alnylam, Ribopharma merge

RNAi companies Alnylam (Cambridge, Mass.) and Ribopharma (Kulmbach, Germany) merged to focus on developing therapeutics in cancer, viral, metabolic, autoimmune and neurological diseases. The combined company, called Alnylam Holding, also raised $24.6 million in a private round, which brings the total money raised by the companies to about $43 million since July 2002. Investors in the round included Polaris Venture Partners; Abingworth Management; Cardinal Partners; Atlas Venture; and ARCH Venture Partners. ...